SCHEMBL4199676

SCHEMBL4199676

CC(CC1CCCCC1)NCc1ccccc1NS(=O)(=O)c1ncc(Br)s1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
ALDH1A1 P00352 4/20 0.36
MAPT P10636 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HTT P42858 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 3/20 0.34
POLB P06746 2/20 0.34
CTSD P07339 1/20 0.31
TP53 P04637 2/20 0.30
THRB P10828 1/20 0.30
PI4KB Q9UBF8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4192908 0.83 MEN1 (0.49) KDM4EPKMALDH1A1MAPTSMN1; SMN2
SCHEMBL4197338 0.82 KDM4E (0.47) KDM4EPKMALDH1A1MAPTSMN1; SMN2
SCHEMBL4197348 0.82 KDM4E (0.40) KDM4EPKMALDH1A1MAPTSMN1; SMN2
SCHEMBL4709060 0.81 KDM4E (0.42) KDM4EPKMALDH1A1MAPTSMN1; SMN2
SCHEMBL4201910 0.81 CNR1 (0.41) KDM4EPKMALDH1A1MAPTSMN1; SMN2
SCHEMBL4204383 0.81 KDM4E (0.40) KDM4EPKMALDH1A1MAPTSMN1; SMN2
SCHEMBL4188022 0.81 KDM4E (0.39) KDM4EPKMALDH1A1MAPTSMN1; SMN2
SCHEMBL4195035 0.80 KDM4E (0.46) KDM4EPKMALDH1A1MAPTSMN1; SMN2
SCHEMBL12050344 0.80 KDM4E (0.55) KDM4EPKMALDH1A1MAPTSMN1; SMN2
SCHEMBL4188285 0.79 KDM4E (0.36) KDM4EPKMALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP claimed
CN-101203504-B Antimicrobial agents RANBAXY LAB LTD 2012-11-14 CN claimed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US claimed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US claimed
CN-101203504-A Antimicrobial agents RANBAXY LAB LTD (IN) 2008-06-18 CN claimed
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP disclosed
CN-101203504-B Antimicrobial agents RANBAXY LAB LTD 2012-11-14 CN disclosed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US disclosed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US disclosed
CN-101203504-A Antimicrobial agents RANBAXY LAB LTD (IN) 2008-06-18 CN disclosed
EP-1879877-A2 ANTIMICROBIAL AGENTS Ranbaxy Laboratories Limited (IN) 2008-01-23 EP disclosed
WO-2006117762-A2 ANTIMICROBIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215764-A1 Antimicrobial agents TUFM, RPS17, HARS1 KDM4E 3328/4885PKM 1855/4885ALDH1A1 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.